Coronavirus has inflicted its first massive hit on Australian markets, amidst growing concerns of infection the companies engaged in the manufacturing of antimicrobial product favorably impacted by COVID-19 as the world fights to shield against it.
The big news related to the coronavirus epidemic is here, Firebrick pharma has developed a nasal spray that can kill 99.97% of the detectable virus.
Yes, you have heard it right, as the health care sector companies are engaged in developing the solutions and performing clinical trials for the prevention and treatment of COVID-19.
One Australia based non listed health care player Firebrick pharmaceutical came up with nasal spray named as Nasodine®, albeit it is yet to approved in Australia.
This nasal spray was developed and tested in laboratories and showed that in vitro, 60-second exposure to Nasodine reduced the amount of detectable virus by 99.97%.
In this article, we are highlighting ASX listed health care players who are engaged either fighting the disease or preventing the disease. The stocks have been in great demand seeing their stock price turn multibaggers in a matter of months!
Stock that is up 6x in 3 Months & 25x in 6 Months! Zoono Group Limited (ASX:ZNO)
Global biotech company Zoono Group Limited (ASX: ZNO) is principally engaged in the development and distribution of environmentally-friendly antimicrobial solutions suitable for surface sanitizers, skincare and mould remediation therapies.
Zoono Group is engaged in the development, manufacturing and distribution of long-lasting & environmentally friendly and scientifically proven antimicrobial solutions, including hand and surface sanitizers that have been proven effective against the coronavirus family.
Z-71 Microbe Shield of Zoono Shows Positive Results Against COVID-19
On 28 February 2020, Zoono group revealed that the Company has received the report for the laboratory tests performed against coronavirus. The results from the study demonstrate that Zoono’s Z-71 Microbe Shield is > 99.99% effective against COVOID-19. Products of the company have been effectively investigated against a range of pathogens for 30 days on surfaces and 24 hours on hands.
Distribution Agreement with Eagle for China
Zoono Group revealed its partnership with Eagle Health Holdings Limited (ASX: EHH) for offline retail sales and distribution of co-branded products (Zoono and Eagle) in China.
In part, due to the Coronavirus epidemic, there is now unprecedented interest in Zoono technology and its proven activity against ‘corona type’ viruses and bacteria as well as its ability of prevention of cross contamination with its 24 hours to 30 day extended efficacy.
The key terms of this distribution agreement are;
- This agreement is for sale of Eagle co-branded products and in offline retail in China and is initially for a three-year term with 5-year rights of renewal;
- A minimum purchase volume in the first 12 months is of NZD $1,500,000, in two years is NZD $2,300,000 and in three years is of NZD $3,100,000;
- Eagle may sell branded products of Zoono as a preferred collaborator subject to good faith negotiations after 12 months in additional channels.
On 28 February 2020, stock of ZNO settled the days’ trade at $1.895, skyrocketing up by 17%. The market capitalisation of the stock stood at around $267 million, with nearly 163.31 million shares outstanding. The 52 weeks high and low price of the stock was noted at $ 2.440 and $0.063, respectively. ZNO stock has generated a positive return of 136% on a year to date basis and an outstanding return of 2,282% in last six months.
Stock that is up 2.21x in just 60 Days! Biotron Limited (ASX:BIT)
An ASX listed health care company Biotron Limited (ASX:BIT) is engaged in research & development as well as commercialisation of pharmaceuticals for targeting significant viral diseases having an unmet medical need. BIT225, Biotron’s lead compound is under phase 2 clinical testing for the treatment of HIV-1 and has a promising pre-clinical program for Hepatitis B (HBV).
The company unveiled that it is in the process of evaluation of many promising compounds for the activity to inhibit coronavirus, including the new novel strain known as 2019-nCoV.
Biotron has more than 30 pharmaceutical drugs with excellent activity against various coronaviruses, including human coronaviruses triggering mild, cold-like signs and SARS coronavirus that was accountable for the epidemic of that virus in 2003.
Related to China coronavirus epidemic (2019), now the company is focusing towards testing a few of these compounds against the new 2019-nCoV.
Clinical & non-clinical programs-
The lead compound of Biotron- BIT225 is under the clinical development for the treatment of Hepatitis C virus (HCV) infections and HIV-1 and has completed seven clinical trials. The compound has been administered in 55 healthy human volunteers, and 94 HIV-1 or HCV infected subjects.
Besides BIT225 development, Biotron also has a portfolio for non-clinical or pre-clinical antiviral programs for the development of the drugs to target various significant well-known and emerging viral infections such as Dengue, Zika and Influenza virus.
The company reported half year results for the first half of the financial year 2020, highlights for the first half are-
- Revenues from ordinary activities reported to be $42,643 up by 132.10% as compared to the previous corresponding period;
- The company has cash and cash equivalents of approximately $8,672,925 at 31 December.
On 28 February 2020, stock of BIT settled the days’ trade at $0.120, edging up by 4%. The market capitalisation of the stock stood at around $80 million, with nearly 701.93 million shares outstanding. The 52 weeks high and low price of the stock was noted at $0.185 and $0.050, respectively. BIT stock has generated a positive return of 121% on a year to date basis and 53% in last six months.
Stock that is up 2x in 30 Days! Holista Colltech Limited (ASX:HCT)
A Perth-headquartered research-driven biotech company Holista Colltech Limited (ASX:HCT) is having extensive operations in Malaysia and seems to have gained attention in the wake of the virus outbreak. Holista is engaged in delivering high class organic ingredients as well as wellness products across the globe.
On 20 February 2020, Holista announced that in partnership with Global Infection Control Consultants LLC, it would co-develop and produce the world’s first nasal sanitising balm NatShieldTM by using Path-Away® in Malaysia. NatShieldTM is all natural, alcohol free, rinse free multipurpose sanitizer.
After a sharp rise in demand following the outbreak of COVID-19, Holista collaborates with three Philippine bottling companies for NatShield™ Sanitiser.
Timeline for development of Nasal Sanitizer-
The Company anticipates all the step related to miniaturing testing and launch of sanitizer in the year 2020, and has a framed timeline-
- Patent filing of this sanitizer is expected in the end of the March 2020;
- Testing would be start in May 2020 followed by its pre-launch in June 2020;
- The product would be launched in the market by July 2020.
Scientific advisory board update-
Path-away® developer and founder of Global Infection Control Consultants LLC (GICC LLC) has joined the Scientific Advisory Board of Holista. Dr Martin graduated from New England Institute of Technology where he studied HVAC and Refrigeration Engineering.
Under his leadership, GICC LCC developed Path-Away®, an all-natural active ingredient that has proven to be effective as a broad spectrum sanitizer.
Currently, Holista has rights for distribution of Path-Away ® in ASEAN, the UK as well as in Europe. Using Path-Away® Sales of a sanitizer significantly increased in Malaysia since the beginning of the year after the outbreak of the coronavirus (Covid-19) that originated in Wuhan, China.
On 28 February 2020, stock of HCT settled the days’ trade at $0.160. The market capitalisation of the stock stood at around $41 million, with nearly 258.42 million shares outstanding. The 52 weeks high and low price of the stock was noted at $ 0.235 and $0.037, respectively. HCT stock has generated a positive return of 95% on a year to date basis and a positive return of 135% in last six months.